Skip to main content
Signal8

NOVAVAX INC (NVAX)

Sector: Biological Products, (No Diagnostic Substances)

Industry: Biotechnology

Novavax, Inc. logo

Novavax, Inc.

NASDAQ:NVAXHealthcare
Pre-0.65%$10.71
Close$10.78+10.22%AH$10.70+0.09%since
Mkt Cap$1.78B
Float156.33M
O/S165.01M
PM VOL4K sh
$ Vol≈$47K
RVOL0.24×
Inst Own70.0%
SI30.3%
Dilution
Novavax, Inc. logoNASDAQ:NVAXPre$10.71-0.65%
Historical Data
DateOpenHighLowCloseVolume
Nov 6, 202610.0610.939.9910.786,292,904
Nov 5, 202610.3410.689.399.788,215,769
Nov 4, 202610.0110.679.8410.656,032,170
Nov 3, 20269.559.959.459.683,464,750
Nov 2, 202610.1110.389.489.534,087,795
Oct 30, 202610.2710.659.9110.084,061,778
Oct 29, 202610.1910.6210.1910.472,800,167
Oct 28, 20269.7910.349.7410.324,748,249
Oct 27, 20269.3710.108.9510.026,774,688
Oct 26, 20269.569.889.269.404,941,085
Oct 23, 20269.849.939.629.704,418,716
Oct 22, 202610.7910.879.559.9912,251,532
Oct 21, 202611.3911.4610.9811.015,440,640
Oct 20, 202610.7511.5710.5511.436,526,442
Oct 19, 202611.2011.9910.7610.826,206,013
Oct 16, 202612.7112.8411.1111.269,891,808
Oct 15, 202612.5013.2512.1812.827,366,884
Oct 14, 202612.6913.3412.5712.648,545,781
Oct 13, 202612.4413.1312.2112.828,399,762
Oct 12, 202612.6112.9612.1912.668,505,453
Analyst Coverage
Analyst Coverage
ConsensusBuy
Price Target
Not available
Ratings Distribution
BUY
17
HOLD
3
SELL
3
TOTAL23
Insider Trades
InsiderTypeShares
King Rachel K. profile photoKing Rachel K.Option Exercise18.9K
MCGLYNN MARGARET G profile photoMCGLYNN MARGARET GOption Exercise18.9K
MOTT DAVID M profile photoMOTT DAVID MOption Exercise18.9K
Alton Gregg H profile photoAlton Gregg HOption Exercise18.9K
MCGLYNN MARGARET G profile photoMCGLYNN MARGARET GOption Exercise18.9K
Alton Gregg H profile photoAlton Gregg HOption Exercise18.9K
Shareholders
70.0%
Institutional
(265)
0.7%
Insiderⓘ
(16)
0.0%
5%+ Owners
(0)
29.3%
Unattributed (incl. retail)ⓘ
Institutional70.0%
Insider0.7%
Unattributed (incl. retail)29.3%
Sources: 13F, Form 4, 13D/13GO/S: 165.0M · as of 31 Oct 2026 · SEC cover page
Insiders & Institutional Holders

Insiders

Top institutional holders

About

Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs.

The company's diverse pipeline includes NVX-CoV2373, a coronavirus vaccine candidate currently undergoing two Phase III trials, one Phase IIb, and one Phase I/II trial. Also featured is NanoFlu, a nanoparticle-based seasonal quadrivalent influenza vaccine in Phase 3 clinical trials. Furthermore, Novavax is advancing ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine, which is in Phase II clinical trials for adults aged 60 and older, and in Phase I for pediatric use.

The company holds a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of its COVID-19 vaccine candidate, NVX-CoV2373. Established in 1987, Novavax, Inc. is headquartered in Gaithersburg, Maryland.

Key Metrics
Market Cap$1.78B
Enterprise Value--
P/E Ratio--
Est. Net Cash/Share--
Institutional Ownership70.04%

based on 165.01M shares outstanding

SectorHealthcare
IndustryBiotechnology
ExchangeNASDAQ
CountryUSUS
IPO DateDec 5, 1995
Shares Outstanding165.01M
Authorized Shares
Float156.33M
52-Week Range
$6.20$13.38
$10.78(64th percentile)
Volume
Average Daily Volume6.45M
6.29M today vs 6.45M avg(-2%)

30d Avg

6.45M

60d Avg

7.18M

90d Avg

6.57M

Earnings
Dividend History
No dividend history available
Compliance Status
Loading compliance data...